Hosted on MSN11mon
AstraZeneca completes Icosavax acquisition for $1.1bn
AstraZeneca has concluded the acquisition of the US-based clinical-stage biopharmaceutical company Icosavax in a $1.1bn deal. The latest development comes after the companies entered a definitive ...
pharmaphorum19h
AZ agrees $1.1bn deal to buy RSV jab developer Icosavax
Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icosavax and its phase 3 ...